TY - JOUR
T1 - Prevalence of electrocardiographic abnormalities and predictors of QTc prolongation in patients with diabetic ketoacidosis
T2 - A retrospective cohort study
AU - Kovichsakul, Winpob
AU - Prakongwong, Varinsawat
AU - Thammakosol, Kitti
AU - Sriphrapradang, Chutintorn
N1 - Publisher Copyright:
© The Author(s) 2026. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
PY - 2026
Y1 - 2026
N2 - Objectives: To determine the prevalence of electrocardiographic (ECG) abnormalities in diabetic ketoacidosis (DKA) patients, evaluate their associations with metabolic parameters, and identify independent predictors of clinical outcomes. Methods: This retrospective study included 374 DKA patients (2012-2023). Baseline clinical characteristics, laboratory data, and initial ECG findings were analyzed. Multivariable logistic regression was performed to assess associations between metabolic parameters and corrected QT (QTc) prolongation, as well as clinical outcomes. Results: Sinus tachycardia occurred in 54.8%, while QTc prolongation was found in 64.7% of patients using Bazett’s formula versus 27.5% using Fridericia’s correction. In multivariable analysis, lower serum bicarbonate levels were independently associated with QTc prolongation using both formulas (Bazett’s: adjusted OR 0.92, 95%CI 0.87–0.98, p=0.007; Fridericia’s: adjusted OR 0.91, 95%CI 0.85–0.97, p=0.002). These associations remained consistent across different QTc thresholds, including high-risk and very high-risk QTc prolongation. However, QTc prolongation was not independently associated with length of stay or in-hospital mortality. Conclusions: QTc prolongation was frequently observed in patients with DKA and showed an association with the severity of metabolic acidosis, particularly reduced serum bicarbonate levels. Given its potential implication for arrhythmogenic risk, careful ECG assessment and monitoring should be considered during the initial evaluation and management of DKA.
AB - Objectives: To determine the prevalence of electrocardiographic (ECG) abnormalities in diabetic ketoacidosis (DKA) patients, evaluate their associations with metabolic parameters, and identify independent predictors of clinical outcomes. Methods: This retrospective study included 374 DKA patients (2012-2023). Baseline clinical characteristics, laboratory data, and initial ECG findings were analyzed. Multivariable logistic regression was performed to assess associations between metabolic parameters and corrected QT (QTc) prolongation, as well as clinical outcomes. Results: Sinus tachycardia occurred in 54.8%, while QTc prolongation was found in 64.7% of patients using Bazett’s formula versus 27.5% using Fridericia’s correction. In multivariable analysis, lower serum bicarbonate levels were independently associated with QTc prolongation using both formulas (Bazett’s: adjusted OR 0.92, 95%CI 0.87–0.98, p=0.007; Fridericia’s: adjusted OR 0.91, 95%CI 0.85–0.97, p=0.002). These associations remained consistent across different QTc thresholds, including high-risk and very high-risk QTc prolongation. However, QTc prolongation was not independently associated with length of stay or in-hospital mortality. Conclusions: QTc prolongation was frequently observed in patients with DKA and showed an association with the severity of metabolic acidosis, particularly reduced serum bicarbonate levels. Given its potential implication for arrhythmogenic risk, careful ECG assessment and monitoring should be considered during the initial evaluation and management of DKA.
KW - clinical outcome
KW - diabetic ketoacidosis
KW - ECG abnormalities
KW - electrolyte imbalance
KW - metabolic acidosis
KW - QT prolongation
KW - QTc prolongation
UR - https://www.scopus.com/pages/publications/105046671145
U2 - 10.1177/20503121261469076
DO - 10.1177/20503121261469076
M3 - Article
AN - SCOPUS:105046671145
SN - 2050-3121
VL - 14
JO - SAGE Open Medicine
JF - SAGE Open Medicine
ER -